Medical Meetings

Learn about the latest myeloma research. Get a front row seat at the most critical medical meetings. Watch Dr. Brian Durie, IMF Chairman, address issues that are important to the entire myeloma community. IMF TV brings it all to you.

Jan
12
Best of ASH 2016
Dr. Brian G.M. Durie discusses key takeaways from the annual conference and explains how this new and important information relates to myeloma patients, caregivers, and other members of the myeloma(...)
Dec
07
ASH 2016: MRD Burden Following ASCT in Multiple Myeloma
The immune system plays an essential role in both promoting and inhibiting the growth of MM. Loss of anti-myeloma immunity involves altered activation and polarization of effector cells as well as(...)
Dec
06
ASH 2016: Updated Analysis of Pollux
Daratumumab is a human monoclonal antibody targeting CD38 that demonstrated superior efficacy in combination with lenalidomide and dexamethasone (DRd) versus lenalidomide and dexamethasone alone (Rd(...)
Dec
06
ASH 2016: Subcutaneous Delivery of Daratumumab in Patients with RRMM
Saad Z. Usmani, MD Levine Cancer Institute Charlotte, NC, USA Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with(...)
Dec
05
ASH 2016: Multiple Myeloma Overview - Dr. Paul Richardson
An overview of the multiple myeloma abstracts presented at ASH 2016 by Dr. Paul Richardson, MD of the Dana-Farber Cancer Institute, Boston, MA.
Dec
05
ASH 2016: Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect® MM Disease Registry
Phase 3 trials demonstrated maintenance therapy after autologous stem cell transplant (ASCT) extended time to progression, progression-free survival, and in some cases overall survival for patients ((...)